ÂÜÀòÂÒÂ×

Oriol Casanovas has a diverse work experience in the life sciences industry. Oriol is currently the Co-Founder and Chief Scientific Officer at AtG Therapeutics since February 2022. Prior to that, they worked at the Catalan Institute of Oncology - IDIBELL, where they held the positions of Senior Group Leader and Investigator (Group Leader) from May 2005 to August 2010.

Oriol has also served as a Scientific Advisor for several pharmaceutical companies such as Novartis, Boehringer-Ingelheim, TevaPharma, IPSEN, and Merck, starting from October 2009. Moreover, they have contributed as a Reviewer/Panel Member for prestigious organizations including the European Research Council, Belgian FWO, Swiss Cancer League, French National Cancer A, and Spanish AEI, starting from April 2007.

Earlier in their career, Oriol gained valuable research experience as a Postdoctoral Research Fellow at the University of California, San Francisco from April 2001 to May 2005. Oriol conducted research at the laboratory of Prof. Douglas Hanahan, focusing on diabetes and cancer. Oriol's academic journey began at the Universitat de Barcelona, where they pursued their PhD from 1996 to 2001.

Oriol Casanovas completed their education in a chronological order. Oriol started their educational journey by earning a Bachelor of Science degree in Biology (Biomedicine) from Universitat de Barcelona between the years 1991 and 1996. Following this, they pursued a Bachelor of Science degree in Pharmacy (Pharmaceutical Sciences) from the same institution from 1992 to 1998. Oriol then continued their academic pursuits by successfully completing a Ph.D. in Cell Biology and Molecular Biology at Universitat de Barcelona from 1996 to 2001. Oriol went on to further enhance their knowledge and expertise in the field by undertaking a PostDoc at the University of California, San Francisco, specializing in Oncology and Cancer Biology, Angiogenesis, and Animal Models of Cancer from 2001 to 2005. Most recently, in 2019 and 2020, they attended UPF Barcelona School of Management, where they focused on Tech Transfer Leadership in Life Sciences with a specific emphasis on Health Innovation and Tech Transfer.